NEXGEL New Strategic Partner
PRESS RELEASE NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete…
Mark ChapmanApril 21, 2026
Early Outcomes from the RENEW Modified Platform Trial of Cellular, Acellular, and Matrix-Like Product Interventions for Diabetic Foot Ulcers
RESEARCH Early Outcomes from the RENEW Modified Platform Trial of Cellular, Acellular, and Matrix-Like Product…
Mark ChapmanApril 11, 2026
Sequence LifeScience, Inc. Receives IRB Approval for a Novel Matched Controls Clinical Trial Targeting Diabetic Foot Ulcers (DFUs)
PRESS RELEASE Sequence LifeScience, Inc. Receives IRB Approval for a Novel Matched Controls Clinical Trial…
Mark ChapmanApril 11, 2026
Sequence LifeScience Enrolls First Patient in Clinical Trial Evaluating Placental Membrane Grafts for Diabetic Foot Ulcers
PRESS RELEASE Sequence LifeScience Enrolls First Patient in Clinical Trial Evaluating Placental Membrane Grafts for…
Mark ChapmanApril 11, 2026
